Signaling

Results of BETonMACE with Kausik Ray, MD, FAHA

Kausik Ray, MD, FAHA explains whether treatment with apabetalone compared to standard of care therapies improves CV outcomes in patients with T2DM and low HDL-C after an acute coronary syndrome (ACS). Dr. Ray is a deputy director of Imperial College London's Clinical Trials Unit. See this study and other late-breaking science presentations on our AHA Science News page.

Science News

Dr. Jeremiah Stamler, 'the father of preventive cardiology,' dies at 102
Impact of the COVID-19 Pandemic on Cardiovascular Science
Anti-dsDNA Antibodies Increase the Cardiovascular Risk in Systemic Lupus Erythematosus Promoting a Distinctive Immune and Vascular Activation
Nidogen-2 Maintains the Contractile Phenotype of Vascular Smooth Muscle Cells and Prevents Neointima Formation via Bridging Jagged1-Notch3 Signaling
Hyperglycaemia Induces Trained Immunity in Macrophages and Their Precursors and Promotes Atherosclerosis

Journals

Decoding the Link Between Inflammation and Pulmonary Arterial Hypertension
Novel Target for Limiting VEGF-A (Vascular Endothelial Growth Factor A)–Induced Vascular Permeability
Tacrolimus Causes Hypertension by Increasing Vascular Contractility via RhoA (Ras Homolog Family Member A)/ROCK (Rho-Associated Protein Kinase) Pathway in Mice
Dynein Coordinates β2-Adrenoceptor-Mediated Relaxation in Normotensive and Hypertensive Rat Mesenteric Arteries
LPA2 Contributes to Vascular Endothelium Homeostasis and Cardiac Remodeling After Myocardial Infarction

Continuing Education

Manesh R. Patel, MD and Amit Khera, MD are photographed bumping fists. Registration Now Open

Mark your calendars now to experience the premier global event focusing on improving health by championing scientific discovery and practice-changing educational content.

We can't wait to see you this November! Even though #AHA21 was fully virtual, our flagship meeting brought us together across the globe. If you missed some of our great programming, now is your chance!

Members can now access informative, practice-changing sessions or earn CE credits for free through a different link. And nonmembers can still purchase our Sessions package or our special CE bundle.

The ATVB Council focuses on arteriosclerosis, thrombosis and vascular biology. The council advances research, addresses prevention, improves diagnosis and treatment, and works actively with other organizations. It shares reliable information through its annual conference, awards and lectures, and in the AHA’s journal, Arteriosclerosis, Thrombosis, and Vascular Biology.


Since 1999, the BCVS Council has advanced understanding of mechanisms of basic cardiovascular regulation to support insights into cardiovascular disease and facilitate new therapies. Emphasis is on integrating molecular/cellular and physiological approaches to address problems relating to genomics, cell signaling, myocardial biology, circulatory physiology, pathophysiology, and peripheral vascular disease.


The GPM Council seeks to advance discovery and translation of biological insights from genetics and omics technologies to improve cardiovascular and brain health through better risk prediction, treatment and prevention for patients. Our expertise spans genetics, genomics, genomic medicine, epigenetics, transcriptomics, metabolomics, proteomics, microbiome, bioinformatics, computational science, and population health.


PVD Council members are focused on improving the care of patients with vascular diseases by advancing science, education, advocacy, and improved healthcare delivery. Members support the AHA mission through active involvement in the council’s scientific initiatives and educational programs, including the annual Scientific Sessions and Vascular Discovery meetings.


American Heart Association Professional Members

Enjoy instant benefits!

  • Free Online Access to AHA Scientific Journals
  • Affiliate with our 16 Scientific Councils
  • Discounts on Scientific Conference Registration and Online Courses